(Q35124000)

6 August 2017

title

Oxcarbazepine for Treatment of Partial Epilepsy: A Review and Recommendations for Clinical Use (English)

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

31 December 2023

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

31 December 2023

author name string

Dieter Schmidt

1

1 reference

6 August 2017

Rajesh Sachdeo

2

1 reference

6 August 2017

language of work or name

1 reference

1 December 2000

1 reference

full work available at URL

6 August 2017

https://api.elsevier.com/content/article/PII:S1525505000901264?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

https://api.elsevier.com/content/article/PII:S1525505000901264?httpAccept=text/plain

31 December 2023

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

31 December 2023

1 reference

6 August 2017

volume

1

1 reference

6 August 2017

issue

6

1 reference

6 August 2017

page(s)

396-405

1 reference

A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group

6 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

Oxcarbazepine: mechanisms of action

31 December 2023

4

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action.

31 December 2023

5

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

The metabolism of 14C-oxcarbazepine in man

31 December 2023

6

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

Clinical pharmacology and pharmacokinetics of oxcarbazepine

31 December 2023

7

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

Pharmacokinetics of 10-OH-carbazepine, the main metabolite of the antiepileptic oxcarbazepine, from serum and saliva concentrations

31 December 2023

9

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

Pharmacokinetics of oxcarbazepine and carbamazepine in human placenta

31 December 2023

10

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites

31 December 2023

11

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group

31 December 2023

12

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

Oxcarbazepine does not affect the anticoagulant activity of warfarin

31 December 2023

14

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine

31 December 2023

15

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women

31 December 2023

17

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

Possible interaction between oxcarbazepine and an oral contraceptive

31 December 2023

19

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

Oxcarbazepine: pharmacokinetic interactions and their clinical relevance

31 December 2023

20

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study

31 December 2023

24

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid

31 December 2023

25

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

Serum sex hormone levels after replacing carbamazepine with oxcarbazepine

31 December 2023

27

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects

31 December 2023

28

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy.

31 December 2023

29

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy

31 December 2023

31

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy

31 December 2023

32

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy

31 December 2023

33

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

Oxcarbazepine: Double-blind, randomized, placebo-control, monotherapy trial for partial seizures

31 December 2023

34

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial

31 December 2023

35

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

Oxcarbazepine (GP 47.680): a possible alternative to carbamazepine?

31 December 2023

37

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

Comparison of oxcarbazepine and carbamazepine: a double-blind study

31 December 2023

38

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment

31 December 2023

39

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

Survey of 260 epileptic patients treated with oxcarbazepine (Trileptal) on a named-patient basis

31 December 2023

40

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy

31 December 2023

42

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

Cross-reactive skin eruption with both carbamazepine and oxcarbazepine

31 December 2023

43

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

Memory and psychomotor effects of oxcarbazepine in healthy human volunteers

31 December 2023

46

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up

31 December 2023

47

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

Cognitive function and anticonvulsant therapy: effect of monotherapy in epilepsy

31 December 2023

48

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review

31 December 2023

49

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

Hyponatraemia during oxcarbazepine therapy

31 December 2023

50

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

Hyponatremic coma under oxcarbazepine therapy

31 December 2023

52

1 reference

https://api.crossref.org/works/10.1006/EBEH.2000.0126

31 December 2023

Identifiers

1 reference

6 August 2017

1 reference